BACKGROUND: Epidemiological data on the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and hepatocellular carcinoma (HCC) are limited. We aimed to investigate the association of SGLT-2i use with HCC and hepatic decompensation in patients with diabetes mellitus (DM)…
BACKGROUND: While sodium-glucose cotransporter 2 inhibitors improves cardiovascular and renal outcomes irrespective of diabetes mellitus (DM) status, their effects in metabolic-dysfunction associated steatotic liver disease (MASLD) patients without diabetes mellitus (DM) are unknown…